| Literature DB >> 30509187 |
Asma Sriha Belguith1, Kaouthar Beltaief2, Mohamed Amine Msolli2, Wahid Bouida2, Hela Abroug3, Manel Ben Fredj3, Imen Zemni3, Mohamed Habib Grissa2, Hamdi Boubaker2, Mohamed Hsairi4, Samir Nouira2.
Abstract
BACKGROUND: We aimed to describe diagnosed acute coronary syndrome (ACS) and its care management and outcomes in emergency departments (EDs) and to determine related cardiovascular risk factors (CVRFs).Entities:
Keywords: Acute coronary syndrome; Cardiovascular risk factors; Epidemiology; Management; Tunisia
Mesh:
Year: 2018 PMID: 30509187 PMCID: PMC6276213 DOI: 10.1186/s12873-018-0201-6
Source DB: PubMed Journal: BMC Emerg Med ISSN: 1471-227X
Chest pain characteristics (n = 1173): February– September; 2015
| N | % | Age (years) | Sex-ratio | |
|---|---|---|---|---|
| All chest pain | 1173 | 100 | 58 (49–68) | 1.81 |
| Cause of chest pain | ||||
| Cardiac | 589 | 51.71 | ||
| Acute coronary syndrome | 566 | 49.69 | 60 (52–70) | 2.07 |
| STEMI | 146 | 60 (52–68) | 3.55 | |
| UA/NSTEMI | 420 | 60 (52–70) | 1.75 | |
| Aortic dissection | 2 | 0.18 | 72 | 2 |
| Pulmonary embolism | 7 | 0.61 | 75 (34–80) | 0.4 |
| Pericarditis/Tamponade | 14 | 1.23 | 52 (39–67.5) | 2.5 |
| Non-cardiac causes | 550 | 48.29 | ||
| Pneumothorax | 9 | 0.79 | 34 (31–46) | 8 |
| Pleurisy | 15 | 1.32 | 61 (55–78) | 1.5 |
| Osteochondritis | 35 | 3.07 | 62 (58–75) | 1.69 |
| Neuralgia of intercostal nerve | 149 | 13.08 | 53 (45–63.75) | 2.36 |
| Digestive pathology | 45 | 3.95 | 59 (46–73.5) | 1.05 |
| Psycho-pathologic disease | 106 | 9.31 | 51 (39.75–60) | 1.08 |
| Irrelevant cause | 191 | 16.77 | 58 (48–71) | 1.58 |
QR quartile range, UA/NSTEMI unstable angina/non-ST-segment-elevation myocardial infarction, STEMI ST segment elevation myocardial infarction
Legend: The half of patient consulting emergency departments for chest pain were diagnosed as acute coronary syndrome especially UA/NSTEMI
Fig. 1Age distribution by ACS and CardioVascular Risk Factors (CVRFs) subgroups (quartile range (years)). Legend: The median age was equal among patient having STEMI and UA/NSTEMI (60 years (IQR 52-68) and 60 years (IQR 52-70), respectively); it was 55 years (IQR 46-66) among patients with no CVRFs and 62 years in those having five CVRFs
Fig. 2Delays of ACS management in Emergency Departments (EDs) (Tunisia). a The median duration between chest pain onset and EDs arrival was 2 h (IQR 2-4 h) for men and 3 h (IQR 2-4 h) for women (p= 0.013). This median duration was higher for the elderly [3 h (IQR:2-4 h)] than for younger patients [2 h (IQR:2-4 h)] (p=0.007) and among patients with UA/NSTEMI [2 h (IQR 1-4 h)] compared to STEMI [2 h (IQR1-3 h)] (p <0.001). b The median decision time (duration between ED admission and starting treatment) was 4 h (IQR: 2- 8 h) for all subgroups, for men and women (p=0.230). This duration increased with age to 3 h (IQR 2-5h) for 30 - 39-year olds, 4 hours (IQR 2-8 h) for 40 – 60-year olds, and 4 h (IQR 2-10 h) for the elderly (p<0.001). The median decision time was 2 h (IQR 0:10-8:30 h) for STEMI and 4 h (IQR 1:00-12:30 h) for UA/NSTEMI patients. c The median ED length of stay (LOS) was 1 hour (IQR 0-1) for regional hospitals and 8 hours (h) (IQR 4-18 h) for university EDs (p<0.001). The LOS in the ED was higher among woman (7 h; IQR: 3- 18 h) than men (6 h; IQR 2-13 h) (p= 0.036). The LOS increased significantly with increasing age; it was 4 hours (IQR: 2-9 h) for patients aged 30-39 years, 6 hours (IQR 2-13 h) for the 40 - 60 years group, and increased to 7 hours (IQR3-18 h) for patients over 60 years (p<0.001). Patients with STEMI had a short median LOS (2 h; (0-5 h) compared to those with UA/NSTEMI [8 h (IQR: 4-20 h)] (p<0.001)
Acute coronary syndrome management according to all ACS, STEMI or UA/NSTEMI
| All ACS ( | STEMI | UA/NSTEMI |
| |
|---|---|---|---|---|
|
| ||||
| Duration between chest pain onset and ED arrival : median (IQR) (hour) | 2 (1-4) | 2 (1-3) | 2 (1-4) | 0.000 |
| Duration between ED admission and treatment starting: median (IQR) (hour) | 3 (1-11) | 2 (0.33-8.7) | 4 (1.12-12.5) | 0.000 |
| ED length of stay: median (IQR) | 6 (2.75-16) | 2 (0.5-5) | 8 (4-20) | 0.000 |
| Medications | ||||
| β blockers | 66 (14.6) | 4 (3.6) | 62 (18.1) | 0.000 |
| Converting enzyme inhibitors | 82 (18.3) | 11 (9.9) | 71 (21.0) | 0.009 |
| In hospital management of ACS | ||||
| Thrombolysis | 41 (7.2)* | 37 (25.3)** | 4 (0.95) | 0.000 |
| Streptokinase | 21 | 19 | 3 | |
| Alteplase | 20 | 18 | 1 | |
| Administered treatment: | ||||
| Aspirin | 499 (91.9) | 133 (97.1) | 366 (90.1) | 0.010 |
| Clopidogrel | 392 (74.1) | 124 (89.9) | 268(68.5) | 0.000 |
| LMWH (HNF) | 254 (49.9) | 84 (64.6) | 170 (44.9) | 0.000 |
| Outcomes | ||||
| MACE | 63(11.1) | 27 (20.0) | 36 (9.1) | 0.001 |
| Deaths | 7 | 3 | 4 | 0.27 |
| Cardiogenic shock | 8 | 4 | 4 | 0.09 |
| Acute Pulmonary Oedema | 43 | 15 | 28 | 0.11 |
| Arrhythmia | 18 | 12 | 6 | 0.000 |
| Others (conduction disorders) | 9 | 7 | 2 | 0.26 |
| Transfer to Cardiology Intensive Care Unit | 269 | 108 (73.9) | 161 (38.3) | 0.000 |
*59 missing values; **20: missing values
ACS Acute coronary syndrome, UA/NSTEMI unstable angina/non-ST-segment-elevation myocardial infarction, STEMI ST segment elevation myocardial infarction, IQR interquartile range. LMWH Low Molecular Weight Heparin. MACE Major adverse cardiac events
Fig. 3Monthly distribution of acute coronary syndrome (Tunisia, 2015). Legend: Significant variations were observed in the monthly ACS distribution, with the highest in April (n=168) and the lowest in July (n=20) (p=0.001)
Crude and age-standardized prevalence rates of acute coronary syndrome
| CPR/100000 inh | r | ASR/100,000 PY | |
|---|---|---|---|
| All | 53.42 | 69.97 | |
| Gender | |||
| Male | 86.6 | 96.24 | |
| Female | 38.62* | 43.70 | |
| Age groups | |||
| < 40 years | 4.60 | 0.64* | |
| 40–60 years | 74.25 | ||
| > 60 years | 175.54 | ||
CPR Crude prevalence rate, r Standardized coefficient, ASR Standardized prevalence rate, PY Person year
Missing value for age (n = 2). *: p < 0.000;
Legend: Prevalence rates were higher in men and population aged more than 60 years
Distribution of conventional cardiovascular risk factors according to all ACS, by STEMI or UA/ NSTEMI
| ALL ACS ( | STEMI ( | UA/NSTEMI ( | ||||
|---|---|---|---|---|---|---|
| Variables | N (%) | OR* [CI95%] | N (%) | OR** [CI95%] | N (%) | OR*** [CI95%] |
| Cardiovascular risk factors type | ||||||
| Not modifiable CVRF | 146 | 420 | ||||
| A/Age correlated with gender | 336 (59.4) | 1.71 [1.29–2.27]d | 90 (61.6) | 2.55 [1.61–4.06]d | 243 (57.9) | 1.47 [1.07–2.02]e |
| B/Vascular personal history | 255 (45.1) | 35 (24.0) | 210 (50.0)a | |||
| Coronary personal history | 210 (37.1) | 1.87 [1.34–2.59]d | 24 (16.4) | 0.64 [0.36–1.14] | 184 (43.8)a | 2.55 [1.79–3.64]d |
| Peripheral arterial history | 38 (6.7) | 6 (04.1) | 31 (7.4) | |||
| Stroke | 50 (8.8) | 9 (06.2) | 40 (09.5) | |||
| Revascularization | 145 (25.6) | 13 (08.9) | 131 (31.2)a | |||
| Modifiable and direct CVRF | ||||||
| C/Treated HTA | 300 (53.0) | 1.23 [0.91–1.68] | 65 (44.5) | 1.08 [0.66–1.75] | 232 (41.8) | 1.26 [0.90–1.75] |
| D/Treated Diabetes type 2 | 248 (43.8) | 2.04 [1.49–2.80]d | 51 (34.9) | 1.30 [0.76–2.21] | 195 (52.4)b | 2.34 [1.67–3.28]d |
| E/Active smoking | 262 (46.3) | 1.50 [1.14–2.00]e | 81 (55.5) | 2.51 [1.63–3.84]d | 178 (36.6)b | 1.18 [0.86–1.60] |
| F/Treated Dyslipidemia | 162 (28.6) | 0.81 [0.57–1.15] | 29 (19.9) | 0.77 [0.43–1.37] | 132 (44.1)b | 0.78 [0.53–1.14] |
| Modifiable and indirect CVRF | ||||||
| G/ Obesity | 147 (26.0) | 1.18 [0.84–1.65] | 34 (23.3) | 1.02 [0.58–1.73] | 111 (39.6) | 1.21 [0.84–1.74] |
| Patients treated by CEI | 192 (33.9) | 0.72 [0.53–0.97]d | 35 (24.0) | 0.56 [0.33–0.93]d | 157 (37.4)a | 0.77 [0.52–1.14] |
| Sum of CVRF | ||||||
| 0 | 39 (6.9) | 1,00 | 10 (6.8) | 1,00 | 29 (06.9) | 1,00 |
| 1 | 105 (18.6) | 2,36 [1.52–3.67]d | 34 (23.3) | 3,24 [1.55–6.79]d | 68 (16.2) | 2,05 [1.25–3.38]d |
| 2 | 130 (23.0) | 3,28 [2.12–5.08]d | 37 (25.3) | 3,64 [1.73–7.65]d | 93 (22.1) | 3,15 [1.94–5.13]d |
| 3 | 119 (21.0) | 3,59 [2.29–5.62]d | 31 (21.2) | 3,65 [1.71–7.80]d | 88 (21.0) | 3,57 [2.17–5.86]d |
| 4 | 96 (17.0) | 4,48 [2.77–7.22]d | 16 (11.0) | 2,91 [1.25–6.77]f | 80 (19.0) | 5,02 [2.98–8.44]d |
| 5 | 49 (08.7) | 4,57 [2.58–8.08]d | 10 (06.8) | 3,64 [1.39–9.47]e | 39 (09.3) | 4,89 [2.64–9.05]d |
| 6 | 19 (03.4) | 4,50 [2.04–9.93]d | 3 (02.1) | 2,77 [0.67–11.36] | 16 (03.8) | 5,09 [2.21–11.76]d |
| 7 | 6 (01.1) | 9,23 [1.79–47.61]e | 2 (01.4) | 4 (01.0)a | 8,28 [1.45–47.39]f | |
Chi 2 pearson test (STEMI vs UA/NSTEMI): ap value < 10−3; b:p value <0.005
Binary logistic analysis*: All SCA vs All chest pain; **All STEMI vs All chest pain: ***: All UA/NSTEMI. vs All chest pain; d: p value < 0.001; e:p value < 0.005; f:p value < 0.05
ACS Acute coronary syndrome, UA/NSTEMI unstable angina/non-ST-segment-elevation myocardial infarction, CVRF cardiovascular risk factors, STEMI ST segment elevation myocardial infarction, OR Odds Ratio, HTA Hypertension, CEI converting enzyme inhibitors
Fig. 4Curve estimation of linear regression for predicting odds ratios through the number of cardiovascular risk factors according to ACS, STEMI or UA/NSTEMI. Legend: a: For all cases of acute coronary syndrome: a significant and strong linear relation was established between the number of cardiovascular risk factors and the OR values (r =0.92; b = 0.62; p <0.0001), b: For UA/NSTEMI linear relation was stronger with (r = 0.96; b =0.795; p <0.0001). c: For STEMI This linear relation was lower with (r =0.49; b = 0.40; p <0.0001).